RxDoctor Payments Data

Gregory Salber, MD

Cardiovascular Disease · Milford, CTNPI 1508279688

Payments from drug & device makers

$923in general payments, 2019–2025

Across 24 payments — averaging $38.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$222
  • Novartis$197
  • Heartflow, Inc.$148
  • Edwards Lifesciences$114
  • Boehringer Ingelheim$109
  • Pfizer$33
  • plus $101 from 5 others

What the payments were for

  • Food & beverage$83090%
  • Education$9410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$923 in reported general payments places this provider in the 40th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$213,393
Medicare patients
897
Services billed
2,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$86,942
JardianceEmpagliflozin30$36,548
EntrestoSacubitril/Valsartan11$18,229
XareltoRivaroxaban14$16,184
Metoprolol Succinate106$1,140
Atorvastatin Calcium142$1,053
Rosuvastatin Calcium61$845
Losartan Potassium50$514
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$433
Amiodarone Hcl12$283
Lisinopril37$253
Amlodipine Besylate45$242
Furosemide50$197
Torsemide13$172
ClopidogrelClopidogrel Bisulfate18$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$86,94269 claims
Boehringer IngelheimJardiance$109$36,54830 claims
NovartisEntresto$197$18,22911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →